Despite various public health strategies, malaria caused by Plasmodium falciparum
parasites remains a major global health challenge that requires development of new …

Infections with Plasmodium falciparum and Plasmodium vivax cause over 600,000 deaths
each year, concentrated in Africa and in young children, but much of the world's population …

Malaria vaccine development has rapidly advanced in the past decade. The very first phase
3 clinical trial of the RTS, S vaccine was completed with over 15,000 African infants and …

A highly protective vaccine will greatly facilitate achieving and sustaining malaria
elimination. Understanding mechanisms of antibody-mediated immunity is crucial for …

Antibodies against the central repeat of the Plasmodium falciparum (Pf) circumsporozoite
protein (CSP) inhibit parasite activity and correlate with protection from malaria. However …

Different types of shed vesicles as, for example, exosomes, plasma-membrane-derived
vesicles or microparticles, are the focus of intense research in view of their potential role in …

A recent study of the RTS, S malaria vaccine, which is based on the circumsporozoite
protein (CSP), demonstrated an increase in efficacy from 50–60% to 80% when using a …

The key step during the initiation of malaria is for motile Plasmodium parasites to exit the
host dermis and infect the liver. During transmission, the parasites in the form of sporozoites …

The motility and invasion of Plasmodium parasites is believed to require a cytoplasmic actin-
myosin motor associated with a cell surface ligand belonging to the TRAP (thrombospondin …

Anti-malarial pre-erythrocytic vaccines (PEV) target transmission by inhibiting human
infection but are currently partially protective. It has been posited, but never demonstrated …